Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.

[1]  H. Rosenberg,et al.  Eosinophils in Health and Disease , 2013 .

[2]  A. Longatto-Filho,et al.  Predictive Biomarkers of Bacillus Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now? , 2012, Advances in urology.

[3]  E. Zwarthoff,et al.  Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review. , 2012, European urology.

[4]  M. Babjuk,et al.  [EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update]. , 2012, Actas urologicas espanolas.

[5]  James J. Lee,et al.  Eosinophils in health and disease: the LIAR hypothesis , 2010, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[6]  L. Martínez-Piñeiro,et al.  Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. , 2009, The Journal of urology.

[7]  H. Trindade,et al.  Efficacy of bacille Calmette-Guérin immunotherapy predicted by expression of antigen-presenting molecules and chemokines. , 2009, Urology.

[8]  V. Sharma,et al.  A novel histologic scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  K. Aozasa,et al.  Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. , 2009, The Journal of urology.

[10]  T. Griffith,et al.  Role of neutrophils in BCG immunotherapy for bladder cancer. , 2008, Urologic oncology.

[11]  H. Herr,et al.  History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. , 2008, The Journal of urology.

[12]  J. Witjes.  Management of BCG failures in superficial bladder cancer: a review. , 2006, European urology.

[13]  J. Witjes,et al.  High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. , 2005, Urology.

[14]  A. Ponticiello,et al.  Analysis of local T lymphocyte subsets upon stimulation with intravesical BCG: a model to study tuberculosis immunity. , 2004, Respiratory medicine.

[15]  A. Zlotta,et al.  Prognosis of T1G3 Tumors: Clinical Factors , 2004 .

[16]  渡邊 悦也.  Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the bladder , 2004 .

[17]  D. Neal,et al.  Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. , 2002, The Journal of urology.

[18]  D. Lamm,et al.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.

[19]  M. Peyromaure,et al.  Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guérin therapy. , 2002, Urology.

[20]  J. Patard,et al.  Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. , 2002, The Journal of urology.

[21]  K. Murphy,et al.  Structure and Specificity of GATA Proteins in Th2 Development , 2001, Molecular and Cellular Biology.

[22]  Laurie H Glimcher,et al.  A Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment , 2000, Cell.

[23]  A. Zlotta,et al.  Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. , 1999, The Journal of urology.

[24]  C. Power,et al.  Mycobacterial Dose Defines the Th1/Th2 Nature of the Immune Response Independently of Whether Immunization Is Administered by the Intravenous, Subcutaneous, or Intradermal Route , 1998, Infection and Immunity.

[25]  A. Stewart,et al.  The National Cancer Data Base report on bladder carcinoma , 1996, Cancer.

[26]  W. Catalona,et al.  Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. , 1994, The Journal of urology.

[27]  J. Fleiss,et al.  Intraclass correlations: uses in assessing rater reliability. , 1979, Psychological bulletin.

[28]  Daan Brandenbarg.  The National. , 1892 .